摘要
目的:探讨趋化因子受体5(CCR5)在乳腺浸润性导管癌组织的表达及意义方法:采用酶标记免疫组织化学方法检测30例乳腺浸润性导管癌及10例乳腺良性肿瘤组织中CCR5的表达情况,并应用ELISA双抗体夹心方法检测了相应患者血清中相关趋化因子MIP1α,MIP1β及RANTES的含量。结果:在乳腺浸润性导管癌组织检测到CCR5的表达(16/30,表达率53.3%),而乳腺良性肿瘤组织中无1例表达;与乳腺良性肿瘤患者相比,在乳腺浸润性导管癌患者血清中RANTES含量明显升高[(41.8±10.2)vs(16.5±2.4)ng/ml,P<0.01],而MIP1α,MIP1β无明显变化。结论:在人乳腺浸润性导管癌组织上发现CCR5的表达,其在乳腺癌的发生发展中可能起重要作用,而RANTES可能是与其相互作用的主要配体。
Objective:To detect the expression of chemokine receptor CCR5 in human invasive ductal breast carcinoma and explore the role of CCR5 in breast cancer.Methods: Thirty samples of invasive ductal breast carcinoma and 10 samples of breast fibroadenoma were analyzed separately by immunohistochemical staining for CCR5 expression. MIP1α,MIP1β and RANTES concentrations were measured by ELISA in the sera of patients. Results: The expression of CCR5 was detected in invasive ductal breast carcinoma (the positive rate was 53.3%) and was not detected in breast fibroadenoma. RANTES concentrations in the serum of breast carcinoma patients increased significantly (P<0.01) while MIP1α and MIP1β changed little compared with those in the sera of breast fibroadenoma patients.Conclusion: CCR5 is expressed in human invasive ductal breast carcinoma,and it may play an important role in the pathogenesis of human breast cancer. RANTES may be the main ligand of CCR5 in the progression of breast cancer.
出处
《第二军医大学学报》
CAS
CSCD
北大核心
2005年第6期657-659,共3页
Academic Journal of Second Military Medical University
